Program
apalutamide
Also written as “Apalutamide”, “JNJ-56021927” and “ARN-509”.
Its studies are mostly in Prostatic Neoplasms · Prostatic Neoplasms, Castration-Resistant · Salivary Gland Neoplasms, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnson | 2711 open or running | phase 4since Sep 26, 2019 | Jul 27, 2010 | Dec 1, 2026phase 3 · NCT03767244 |
| Sumitomo Pharma | 10 open or running | phase 1since Dec 7, 2020 | Dec 7, 2020 | none ahead |
Also a collaborator on its studies: Bayer.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 13 studies since Jul 27, 2010.
- Aug 21, 2015Phase 3 study in Prostatic NeoplasmsJohnson & Johnson · NCT02531516 · 1,503 enrolled · United States, Argentina, Belgium and more
- Oct 15, 20152 phase 1 studiesJohnson & Johnson · NCT02578797, NCT02592317
- Jun 29, 2016Phase 1 study in HealthyJohnson & Johnson · NCT02835508 · 18 enrolled · Japan
- Sep 15, 2016Phase 2 study in Prostatic Neoplasms, Castration-ResistantJohnson & Johnson · NCT02906605 · United States
- Oct 4, 2016Phase 1 study in Prostatic NeoplasmsJohnson & Johnson · NCT02924766 · 34 enrolled · United States, Canada
- May 2, 2018Phase 1 study in Prostatic NeoplasmsJohnson & Johnson · NCT03523442 · 19 enrolled · China
- Dec 5, 2018Phase 3 study in Prostatic NeoplasmsJohnson & Johnson · NCT03767244 · 2,517 enrolled · United States, Argentina, Australia and more
- Jan 11, 2019Phase 1 study in HealthyJohnson & Johnson · NCT03802682 · 12 enrolled · Belgium
- Sep 26, 2019Phase 4 study in Prostatic NeoplasmsJohnson & Johnson · NCT04108208 · 75 enrolled · China
- Nov 5, 2019Phase 1 study in Hepatic ImpairmentJohnson & Johnson · NCT04154774 · 18 enrolled · United States
- Mar 26, 2020Phase 2 study in Salivary Gland NeoplasmsJohnson & Johnson · NCT04325828 · 31 enrolled · Japan
- Sep 17, 2020Phase 3 study in Prostatic NeoplasmsJohnson & Johnson · NCT04557059 · 691 enrolled · United States, Australia, Austria and more
- Dec 7, 2020Sumitomo Pharma's first study: phase 1 study in Metastatic Castration-Resistant Prostate CancerNew to Sumitomo PharmaSumitomo Pharma · NCT04666129 · 48 enrolled · United States
- May 23, 2023Phase 3 study in Metastatic Castrate-sensitive Prostate CancerJohnson & Johnson · NCT05884398 · 420 enrolled · United States, Australia, Brazil and more
Ahead
- Dec 1, 2026Primary completion: phase 3 study in Prostatic NeoplasmsJohnson & Johnson · NCT03767244
- Mar 1, 2027Primary completion: phase 3 study in Prostatic NeoplasmsJohnson & Johnson · NCT02531516
- Aug 27, 2029Primary completion: phase 3 study in Prostatic NeoplasmsJohnson & Johnson · NCT04557059
TargetBeta
“A small molecule and androgen receptor (AR) antagonist ”NCIt, by rule
“Androgen Receptor antagonist”ChEMBL 37, by rule
Other programs on AR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| enzalutamiderule | Astellas Pharma | phase 4 | 69 |
| darolutamiderule | Bayer | phase 4 | 26 |
| Clascoteronerule | cassiopea-spa | phase 4 | 19 |
| ostarinerule | gtx | phase 3 | 15 |
| rezvilutamiderule | Jiangsu HengRui Medicine | phase 3 | 13 |
| dezandrodegrule | Bristol-Myers Squibb | phase 3 | 5 |
| Cyproterone Acetaterule | Eurofarma Laboratorios | phase 3 | 4 |
| Androgen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0915 | Johnson & Johnson | phase 3 | 3 |
| HRS-5041 | Jiangsu HengRui Medicine | phase 2 | 6 |
| luxdegalutamide | Novartis | phase 2 | 3 |
| luxdegalutamide | Novartis | phase 2 | 2 |
| Androgen Receptor Degrader AZD9750rule | AstraZeneca | phase 2 | 1 |
Studies
All 28 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT05884398Metastatic Castrate-sensitive Prostate Cancer · United States, Australia, Brazil and more | 3 | Active, not recruiting | Johnson & Johnson | Oct 12, 2026 | 420 |
| NCT04666129Metastatic Castration-Resistant Prostate Cancer · United States | 1 | Completed | Sumitomo Pharma | May 28, 2024 | 48 |
| NCT04557059Prostatic Neoplasms · United States, Australia, Austria and more | 3 | Active, not recruiting | Johnson & Johnson | Aug 27, 2029 | 691 |
| NCT04325828Salivary Gland Neoplasms · Japan | 2 | Active, not recruiting | Johnson & Johnson | Jun 9, 2021 | 31 |
| NCT04154774Hepatic Impairment · United States | 1 | Completed | Johnson & Johnson | Feb 10, 2025 | 18 |
| NCT04108208Prostatic Neoplasms · China | 4 | Completed | Johnson & Johnson | Jun 1, 2023 | 75 |
| NCT03802682Healthy · Belgium | 1 | Completed | Johnson & Johnson | Apr 11, 2019 | 12 |
| NCT03767244Prostatic Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Johnson & Johnson | Dec 1, 2026 | 2,517 |
| NCT03523442Prostatic Neoplasms · China | 1 | Active, not recruiting | Johnson & Johnson | Jul 9, 2019 | 19 |
| NCT02924766Prostatic Neoplasms · United States, Canada | 1 | Completed | Johnson & Johnson | Jul 18, 2019 | 34 |
| NCT02906605Prostatic Neoplasms, Castration-Resistant · United States | 2 | Withdrawn | Johnson & Johnson | Sep 2018 | 0 |
| NCT02835508Healthy · Japan | 1 | Completed | Johnson & Johnson | Dec 2016 | 18 |
| NCT02592317Prostatic Neoplasms, Castration-Resistant · Moldova, Spain | 1 | Active, not recruiting | Johnson & Johnson | Nov 7, 2016 | 23 |
| NCT02578797Prostatic Neoplasms · United States, Canada, Moldova, Republic of and more | 1 | Completed | Johnson & Johnson | Sep 20, 2016 | 45 |
| NCT02531516Prostatic Neoplasms · United States, Argentina, Belgium and more | 3 | Active, not recruiting | Johnson & Johnson | Mar 1, 2027 | 1,503 |
| NCT02524717Hepatic Impairment · United States | 1 | Completed | Johnson & Johnson | Feb 9, 2017 | 24 |
| NCT02489318Prostatic Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Johnson & Johnson | Sep 7, 2020 | 1,052 |
| NCT02257736Prostatic Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Johnson & Johnson | Mar 19, 2018 | 982 |
| NCT02230033Healthy · United States | 1 | Completed | Johnson & Johnson | Dec 2014 | 45 |
| NCT02162836Prostatic Neoplasms, Castration-Resistant · Japan | 1 | Completed | Johnson & Johnson | May 27, 2019 | 6 |
| NCT02160756Healthy | 1 | Completed | Johnson & Johnson | Nov 2014 | 75 |
| NCT02123758Prostatic Neoplasms · United States, Canada, Netherlands and more | 1 | Active, not recruiting | Johnson & Johnson | Jun 27, 2016 | 57 |
| NCT02031666Healthy · United States | 1 | Completed | Johnson & Johnson | Apr 2014 | 120 |
| NCT01946204Prostatic Neoplasms · United States, Australia, Austria and more | 3 | Active, not recruiting | Johnson & Johnson | May 19, 2017 | 1,207 |
| NCT01822041Healthy · Netherlands | 1 | Completed | Johnson & Johnson | Jun 2013 | 12 |
| NCT01792687Prostatic Neoplasms · United States | 1 | Completed | Johnson & Johnson | May 10, 2014 | 6 |
| NCT01790126Prostatic Neoplasms · United States | 2 | Completed | Johnson & Johnson | Mar 1, 2019 | 90 |
| NCT01171898Prostatic Neoplasms · United States | 2 | Completed | Johnson & Johnson | Aug 20, 2012 | 127 |
How it is read
Names in the registry
- “Apalutamide”, 18 entries
- “JNJ-56021927”, 4 entries
- “ARN-509”, 3 entries
- “JNJ 56021927”, 1 entry
- “apalutamide”, 1 entry
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 19 studies
- Prostatic Neoplasms, Castration-Resistant, 3 studies
- Salivary Gland Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.